Regression of melanoma metastases following treatment with the n-bisphosphonate zoledronate and localised radiotherapy

Clinical Immunology

Volumn 131, Issue 3, 2009, Pages 367-373

  Laggner, U ^a,b   Lopez, J S ^b   Perera, G ^a,b   Warbey, V S ^b   Sita Lumsden, A ^a,b   O'Doherty, M J ^b   Hayday, A ^c   Harries, M ^b   Nestle, F O ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Bisphosphonates; Immunotherapy; Melanoma

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DACARBAZINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE METASTASIS; CANCER REGRESSION; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; DRUG MECHANISM; HUMAN; IMMUNE SYSTEM; LUNG METASTASIS; MELANOMA; METASTASIS INHIBITION; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SACROILIAC JOINT; SHORT SURVEY; SUPPRESSOR CELL; T DELTA CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR CELL;

APOPTOSIS; BONE NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; MELANOMA; MIDDLE AGED; T-LYMPHOCYTES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 67349188865     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.01.008     Document Type: Short Survey

References (46)

1. Crosby T., Fish R., Coles B., and Mason M.D. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst. Rev. (2000) CD001215
2. Nathanson L. Spontaneous regression of malignant melanoma: a review of the literature on incidence, clinical features, and possible mechanisms. Natl. Cancer Inst. Monogr. 44 (1976) 67-76
3. Wang T.S., Lowe L., Smith II J.W., Francis I.R., Sondak V.K., Dworzanian L., Finkelstein S., Slingluff Jr. C.L., and Johnson T.M. Complete spontaneous regression of pulmonary metastatic melanoma. Dermatol. Surg. 24 (1998) 915-919
4. Morita C.T., Jin C., Sarikonda G., and Wang H. Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vgamma2Vdelta2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. Immunol. Rev. 215 (2007) 59-76
5. Chakraborty M., Abrams S.I., Coleman C.N., Camphausen K., Schlom J., and Hodge J.W. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res. 64 (2004) 4328-4337
6. Reits E.A., Hodge J.W., Herberts C.A., Groothuis T.A., Chakraborty M., Wansley E.K., Camphausen K., Luiten R.M., de Ru A.H., Neijssen J., Griekspoor A., Mesman E., Verreck F.A., Spits H., Schlom J., van Veelen P., and Neefjes J.J. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J. Exp. Med. 203 (2006) 1259-1271
7. Zitvogel L., Apetoh L., Ghiringhelli F., Andre F., Tesniere A., and Kroemer G. The anticancer immune response: indispensable for therapeutic success?. J. Clin. Invest. 118 (2008) 1991-2001
8. Stewart F.W. Experiences in spontaneous regression of neoplastic disease in man. Tex. Rep. Biol. Med. 10 (1952) 239-253
9. Maurer S., and Kolmer K.F. Spontaneous regression of advanced malignant melanoma. Onkologie 21 (1998) 14-18
10. High W.A., Stewart D., Wilbers C.R., Cockerell C.J., Hoang M.P., and Fitzpatrick J.E. Completely regressed primary cutaneous malignant melanoma with nodal and/or visceral metastases: a report of 5 cases and assessment of the literature and diagnostic criteria. J. Am. Acad. Dermatol. 53 (2005) 89-100
11. Clemente C.G., Mihm Jr. M.C., Bufalino R., Zurrida S., Collini P., and Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77 (1996) 1303-1310
12. Parmiani G., Castelli C., Rivoltini L., Casati C., Tully G.A., Novellino L., Patuzzo A., Tosi D., Anichini A., and Santinami M. Immunotherapy of melanoma. Semin. Cancer Biol. 13 (2003) 391-400
13. Hollenbeak C.S., Todd M.M., Billingsley E.M., Harper G., Dyer A.M., and Lengerich E.J. Increased incidence of melanoma in renal transplantation recipients. Cancer 104 (2005) 1962-1967
14. Jensen P., Moller B., and Hansen S. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J. Am. Acad. Dermatol. 42 (2000) 307
15. Kirkwood J.M., Tarhini A.A., Panelli M.C., Moschos S.J., Zarour H.M., Butterfield L.H., and Gogas H.J. Next generation of immunotherapy for melanoma. J. Clin. Oncol. 26 (2008) 3445-3455
16. Nestle F.O. Vaccines and melanoma. Clin. Exp. Dermatol. 27 (2002) 597-601
17. Moschos S.J., Mandic M., Kirkwood J.M., Storkus W.J., and Lotze M.T. Focus on FOCIS: interleukin 2 treatment associated autoimmunity. Clin. Immunol. 127 (2008) 123-129
18. Roelofs A.J., Thompson K., Gordon S., and Rogers M.J. Molecular mechanisms of action of bisphosphonates: current status. Clin. Cancer Res. 12 (2006) 6222s-6230s
19. Green J.R., and Clezardin P. Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am. J. Clin. Oncol. 25 (2002) S3-9
20. Hayday A.C. [gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu. Rev. Immunol. 18 (2000) 975-1026
21. Kabelitz D., Wesch D., and He W. Perspectives of gammadelta T cells in tumor immunology. Cancer Res. 67 (2007) 5-8
22. Liu Z., Guo B.L., Gehrs B.C., Nan L., and Lopez R.D. Ex vivo expanded human Vgamma9Vdelta2+gammadelta-T cells mediate innate antitumor activity against human prostate cancer cells in vitro. J. Urol. 173 (2005) 1552-1556
23. Kabelitz D., Wesch D., Pitters E., and Zoller M. Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo. J. Immunol. 173 (2004) 6767-6776
24. Constant P., Davodeau F., Peyrat M.A., Poquet Y., Puzo G., Bonneville M., and Fournie J.J. Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. Science 264 (1994) 267-270
25. Tanaka Y., Morita C.T., Tanaka Y., Nieves E., Brenner M.B., and Bloom B.R. Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature 375 (1995) 155-158
26. Gober H.J., Kistowska M., Angman L., Jeno P., Mori L., and De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med. 197 (2003) 163-168
27. Bonneville M., and Fournie J.J. Sensing cell stress and transformation through Vgamma9Vdelta2 T cell-mediated recognition of the isoprenoid pathway metabolites. Microbes Infect. 7 (2005) 503-509
28. Dieli F., Vermijlen D., Fulfaro F., Caccamo N., Meraviglia S., Cicero G., Roberts A., Buccheri S., D'Asaro M., Gebbia N., Salerno A., Eberl M., and Hayday A.C. Targeting human {gamma}{delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 67 (2007) 7450-7457
29. Rincon-Orozco B., Kunzmann V., Wrobel P., Kabelitz D., Steinle A., and Herrmann T. Activation of V gamma 9V delta 2 T cells by NKG2D. J. Immunol. 175 (2005) 2144-2151
30. Steinle A., Li P., Morris D.L., Groh V., Lanier L.L., Strong R.K., and Spies T. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics 53 (2001) 279-287
31. Vetter C.S., Groh V., thor Straten P., Spies T., Brocker E.B., and Becker J.C. Expression of stress-induced MHC class I related chain molecules on human melanoma. J. Invest. Dermatol. 118 (2002) 600-605
32. Poggi A., Zocchi M.R., Costa P., Ferrero E., Borsellino G., Placido R., Galgani S., Salvetti M., Gasperini C., Ristori G., Brosnan C.F., and Battistini L. IL-12-mediated NKRP1A up-regulation and consequent enhancement of endothelial transmigration of V delta 2+ TCR gamma delta+ T lymphocytes from healthy donors and multiple sclerosis patients. J. Immunol. 162 (1999) 4349-4354
33. Cretney E., Shanker A., Yagita H., Smyth M.J., and Sayers T.J. TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol. Cell Biol. 84 (2006) 87-98
34. Vermijlen D., Ellis P., Langford C., Klein A., Engel R., Willimann K., Jomaa H., Hayday A.C., and Eberl M. Distinct cytokine-driven responses of activated blood gammadelta T cells: insights into unconventional T cell pleiotropy. J. Immunol. 178 (2007) 4304-4314
35. Viey E., Fromont G., Escudier B., Morel Y., Da Rocha S., Chouaib S., and Caignard A. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma. J. Immunol. 174 (2005) 1338-1347
36. Dieli F., Gebbia N., Poccia F., Caccamo N., Montesano C., Fulfaro F., Arcara C., Valerio M.R., Meraviglia S., Di Sano C., Sireci G., and Salerno A. Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 102 (2003) 2310-2311
37. Marten A., Lilienfeld-Toal M., Buchler M.W., and Schmidt J. Zoledronic acid has direct antiproliferative and antimetastatic effect on pancreatic carcinoma cells and acts as an antigen for delta2 gamma/delta T cells. J. Immunother. 30 (2007) 370-377
38. Wilhelm M., Kunzmann V., Eckstein S., Reimer P., Weissinger F., Ruediger T., and Tony H.P. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 102 (2003) 200-206
39. Kobayashi H., Tanaka Y., Yagi J., Osaka Y., Nakazawa H., Uchiyama T., Minato N., and Toma H. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol. Immunother. 56 (2007) 469-476
40. Tsagozis P., Eriksson F., and Pisa P. Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages. Cancer Immunol. Immunother. 57 (2008) 1451-1459
41. Giraudo E., Inoue M., and Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J. Clin. Invest. 114 (2004) 623-633
42. Melani C., Sangaletti S., Barazzetta F.M., Werb Z., and Colombo M.P. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res. 67 (2007) 11438-11446
43. Sassano A., and Platanias L.C. Statins in tumor suppression. Cancer Lett. 260 (2008) 11-19
44. Zheng X., Cui X.X., Avila G.E., Huang M.T., Liu Y., Patel J., Kong A.N., Paulino R., Shih W.J., Lin Y., Rabson A.B., Reddy B.S., and Conney A.H. Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice. Clin. Cancer Res. 13 (2007) 5480-5487
45. Issat T., Nowis D., Legat M., Makowski M., Klejman M.P., Urbanski J., Skierski J., Koronkiewicz M., Stoklosa T., Brzezinska A., Bil J., Gietka J., Jakobisiak M., and Golab J. Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo. Int. J. Oncol. 30 (2007) 1413-1425
46. Mausner-Fainberg K., Luboshits G., Mor A., Maysel-Auslender S., Rubinstein A., Keren G., and George J. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis 197 (2008) 829-839